New Clinical Evidence for ClotChek™ Published
A study published in Thrombosis and Haemostasis confirms the clinical utility of the ClotChek™ device in patients treated with Factor Xa inhibitors.
New clinical evidence for the ClotChek™ device has been published in the peer-reviewed journal Thrombosis and Haemostasis. The study focused on the diagnostic capabilities of the device in patients undergoing anticoagulant therapy.
The article, titled "Clinical Validation of a Point-of-Care Whole Blood Coagulometer in Patients on Factor Xa Inhibitors," details how ClotChek™ can accurately measure clotting times in individuals receiving Factor Xa inhibitor treatment. This is significant as these medications can interfere with standard coagulation tests.
Findings from the research indicate that ClotChek™ provides a reliable and rapid point-of-care option for assessing coagulation status. This may enable clinicians to make quicker, more informed treatment decisions for patients during active therapy.
The device's ability to operate with whole blood and deliver results promptly makes it a valuable tool in clinical settings, particularly where rapid diagnostics are crucial for patient safety and treatment optimization.